What is the official website of Neurologybytes ?

The official website of Neurologybytes is http://www.neurologybytes.com.

What is Neurologybytes's cybersecurity risk score?

Neurologybytes has an AI-generated cybersecurity risk score of 770 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Neurologybytes experienced?

According to Rankiteo, Neurologybytes currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Neurologybytes been affected by any supply chain cyber incidents ?

According to Rankiteo, Neurologybytes has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Neurologybytes have SOC 2 Type 1 certification ?

According to Rankiteo, Neurologybytes is not certified under SOC 2 Type 1.

Does Neurologybytes have SOC 2 Type 2 certification ?

According to Rankiteo, Neurologybytes does not hold a SOC 2 Type 2 certification.

Does Neurologybytes comply with GDPR ?

According to Rankiteo, Neurologybytes is not listed as GDPR compliant.

Does Neurologybytes have PCI DSS certification ?

According to Rankiteo, Neurologybytes does not currently maintain PCI DSS compliance.

Does Neurologybytes comply with HIPAA ?

According to Rankiteo, Neurologybytes is not compliant with HIPAA regulations.

Does Neurologybytes have ISO 27001 certification ?

According to Rankiteo,Neurologybytes is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Neurologybytes operate in ?

Neurologybytes operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Neurologybytes have ?

Neurologybytes employs approximately None employees people worldwide.

Does Neurologybytes own any subsidiaries ?

Neurologybytes presently has no subsidiaries across any sectors.

How many LinkedIn followers does Neurologybytes have ?

Neurologybytes's official LinkedIn profile has approximately followers.

What is the NAICS classification code for Neurologybytes ?

Neurologybytes is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Neurologybytes have a Crunchbase profile ?

No, Neurologybytes does not have a profile on Crunchbase.

Does Neurologybytes have a LinkedIn profile ?

Yes, Neurologybytes maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/neurologybytes.

How many cybersecurity incidents has Neurologybytes experienced ?

As of August 5, 2026, Rankiteo reports that Neurologybytes has not experienced any cybersecurity incidents.

How many peer or competitor companies does Neurologybytes have ?

Neurologybytes has an estimated 5,721 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Neurologybytes

Boost Score +25 with badge (5 left)

770

/1000

Fair

795

/1000

Fair

Neurologybytes Vendor Cyber Rating & Cyber Score

neurologybytes.com

Add Your Compliance Badge

Neurologybytes. A place for healthcare professionals to learn, connect, share and stay informed on all things neurology, including migraine, headache and multiple sclerosis. Become a part of this premium peer-to-peer knowledge hub today.

Neurologybytes A.I CyberSecurity Scoring

Scoring History

Neurologybytes

Neurologybytes CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Neurologybytes Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Neurologybytes

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Neurologybytes in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Neurologybytes in 2026.

Incident Types Neurologybytes vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Neurologybytes in 2026.

Incident History - Neurologybytes (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Neurologybytes Subsidiaries

Neurologybytes

Pharmaceutical Manufacturing

Website: http://www.neurologybytes.com

Company Size: 10,001+ employees

Teva PharmaceuticalsPharmaceutical Manufacturing

PLIVAPharmaceutical Manufacturing

Teva SantéPharmaceutical Manufacturing

Actu-MigraineFabrication de produits pharmaceutiques

Watson Pharma Pvt LtdPharmaceutical Manufacturing

Loading…

Neurologybytes Similar Companies

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Loading…

NEWS

Neurologybytes CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-45537

SUMMARY

OpenSIPS is a Session Initiation Protocol (SIP) server implementation. In versions prior to 3.6.6 and 4.0.0-rc1, the construct_uri() function concatenates multiple URI components (protocol, username, domain, port, params) into a fixed 1024-byte global BSS buffer without any bounds checking. When a routing script calls construct_uri() with an attacker-controlled username, a combined component length exceeding 1024 bytes overflows the buffer, corrupting adjacent global data with attacker-controlled content. The overflow reaches disable_503_translation, a global flag controlling SIP 503 response handling, allowing an attacker to deterministically set the flag via the URI username and alter the server's routing behavior for subsequent messages. Because the same buffer is shared with contact_builder(), the overflow also corrupts that function's data, and without a memory sanitizer the adjacent globals are silently overwritten on every request containing a long username. This issue has been fixed in versions 3.6.6 and 4.0.0-rc1.

Published

Date2026-08-04

Updated

Date2026-08-04

RISK INFORMATION (Score: 9.1)

cvss3

Base Score: 9.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:H/A:H

Impact Score

5.2

Exploitability

3.9

REFERENCES

CVE-2026-18819

SUMMARY

A security vulnerability has been detected in RackTables up to 0.22.0/e5fff9f8aab339798ed47e8c6d7d977ed97a82bd. This vulnerability affects unknown code. The manipulation leads to cross-site request forgery. The attack is possible to be carried out remotely. The exploit has been disclosed publicly and may be used. The project maintainer confirms: "[I]t seems plausible, in that RackTables does not at this time have any CSRF prevention. You may assign a CVE ID to this, but there is no guarantee it will be handled in urgent, or even timely, manner, or at all."

Published

Date2026-08-04

Updated

Date2026-08-04

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 5.0

Complexity: LOW

AV:N/AC:L/Au:N/C:N/I:P/A:N

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-18818

SUMMARY

A weakness has been identified in Ehco1996 django-sspanel up to 2023.12.26. This affects the function TicketDetailView of the file apps/sspanel/views.py of the component Support Ticket Handler. Executing a manipulation can lead to authorization bypass. The attack can be executed remotely. The vendor was contacted early about this disclosure but did not respond in any way. This vulnerability only affects products that are no longer supported by the maintainer.

Published

Date2026-08-04

Updated

Date2026-08-04

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-70620

SUMMARY

Odysseus before commit 87babb5 contains a server-side request forgery vulnerability that allows admin-privileged attackers to direct the server to probe internal network resources by supplying arbitrary URLs to the embedding endpoint configuration without scheme, host, IP range, or DNS rebind validation. Attackers can submit loopback addresses, RFC 1918 ranges, or link-local addresses through the embedding endpoint API to partially read responses from cloud instance metadata services, internal APIs, and other hosts reachable from the server.

Published

Date2026-08-04

Updated

Date2026-08-04

RISK INFORMATION (Score: 6.8)

cvss3

Base Score: 6.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:C/C:H/I:N/A:N

cvss4

Base Score: 6.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:N/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

2.3

REFERENCES

CVE-2026-70619

SUMMARY

Odysseus before commit bf325f6 contains a missing authorization vulnerability that allows authenticated non-admin users to manage server-wide embedding backend configuration by invoking endpoint management routes that verify session authentication but omit the admin authorization guard. Attackers can supply an attacker-controlled URL to overwrite the embedding backend persisted in the endpoint configuration file and process environment, causing all subsequent embedding operations including chat messages, RAG queries, memory entries, and vault text to be transmitted in plaintext to the attacker-controlled destination, or delete the endpoint configuration to deny embedding service to all users.

Published

Date2026-08-04

Updated

Date2026-08-04

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…